Prostate Cancer Early Detection Clinical Practice Guidelines in Oncology NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform
Search Results
Prostate Cancer Early Detection
Mark H. Kawachi, Robert R. Bahnson, Michael Barry, J. Erik Busby, Peter R. Carroll, H. Ballentine Carter, William J. Catalona, Michael S. Cookson, Jonathan I. Epstein, Ruth B. Etzioni, Veda N. Giri, George P. Hemstreet III, Richard J. Howe, Paul H. Lange, Hans Lilja, Kevin R. Loughlin, James Mohler, Judd Moul, Robert B. Nadler, Stephen G. Patterson, Joseph C. Presti, Antoinette M. Stroup, Robert Wake, and John T. Wei
Prostate Cancer Early Detection, Version 2.2015
Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Daniel A. Barocas, Erik P. Castle, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Thomas Farrington, George P. Hemstreet III, Mark H. Kawachi, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shaneyfelt, Marc C. Smaldone, Geoffrey Sonn, Preston Sprenke, Andrew J. Vickers, Robert Wake, Dorothy A. Shead, and Deborah Freedman-Cass
Prostate Cancer Early Detection provide a set of sequential recommendations detailing a screening and evaluation strategy for maximizing the detection of prostate cancer that is potentially curable and that, if left undetected, represents a risk to the
Prostate Cancer Early Detection, Version 1.2014
Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Daniel A. Barocas, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Veda N. Giri, George P. Hemstreet III, Mark H. Kawachi, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shanefelt, Andrew J. Vickers, Robert Wake, Dorothy A. Shead, and Maria Ho
to: Integrate into professional practice the updates to NCCN Guidelines for Prostate Cancer Early Detection Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Prostate Cancer Early Detection
NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016
Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Erik P. Castle, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Thomas Farrington, George P. Hemstreet III, Mark H. Kawachi, Simon Kim, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Kelvin A. Moses, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shaneyfelt, Marc C. Smaldone, Geoffrey Sonn, Preston Sprenkle, Andrew J. Vickers, Robert Wake, Dorothy A. Shead, and Deborah A. Freedman-Cass
activity, participants will be able to: Integrate into professional practice the updates to NCCN Guidelines for Prostate Cancer Early Detection Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Prostate
The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals
George Zogopoulos, Ido Haimi, Shenin A. Sanoba, Jessica N. Everett, Yifan Wang, Bryson W. Katona, James J. Farrell, Aaron J. Grossberg, Salvatore Paiella, Kelsey A. Klute, Yan Bi, Michael B. Wallace, Richard S. Kwon, Elena M. Stoffel, Raymond C. Wadlow, Daniel A. Sussman, Nipun B. Merchant, Jennifer B. Permuth, Talia Golan, Maria Raitses-Gurevich, Andrew M. Lowy, Joy Liau, Joanne M. Jeter, James M. Lindberg, Daniel C. Chung, Julie Earl, Teresa A. Brentnall, Kasmintan A. Schrader, Vivek Kaul, Chenchan Huang, Hersh Chandarana, Caroline Smerdon, John J. Graff, Fay Kastrinos, Sonia S. Kupfer, Aimee L. Lucas, Rosalie C. Sears, Randall E. Brand, Giovanni Parmigiani, Diane M. Simeone, and on behalf of the PRECEDE Consortium
cancer stage at diagnosis and evasiveness to systemic therapies. 4 Thus, because 80% of patients with PC are diagnosed with advanced-stage disease, early detection offers an opportunity to markedly impact survival. To this end, patients with stage IA
Early Detection and Biomarkers in Pancreatic Cancer
David E. Misek, Tasneem H. Patwa, David M. Lubman, and Diane M. Simeone
JA . Early detection of unsuspected colon cancers in asymptomatic people . Dis Colon Rectum 1993 ; 36 : 411 . 14. Mandel JB Church JH Snover TR . Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota
NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023
Featured Updates to the NCCN Guidelines
Kelvin A. Moses, Preston C. Sprenkle, Clinton Bahler, Geoffrey Box, Sigrid V. Carlsson, William J. Catalona, Douglas M. Dahl, Marc Dall’Era, John W. Davis, Bettina F. Drake, Jonathan I. Epstein, Ruth B. Etzioni, Thomas A. Farrington, Isla P. Garraway, David Jarrard, Eric Kauffman, Deborah Kaye, Adam S. Kibel, Chad A. LaGrange, Paul Maroni, Lee Ponsky, Brian Reys, Simpa S. Salami, Alejandro Sanchez, Tyler M. Seibert, Terrence M. Shaneyfelt, Marc C. Smaldone, Geoffrey Sonn, Mark D. Tyson, Neha Vapiwala, Robert Wake, Samuel Washington, Alice Yu, Bertram Yuh, Ryan A. Berardi, and Deborah A. Freedman-Cass
, 2023; Expiration date: March 10, 2024 Learning Objectives: Upon completion of this activity, participants will be able to: • Integrate into professional practice the updates to the NCCN Guidelines for Prostate Cancer Early Detection
NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection
Peter H. Carroll and James L. Mohler
“There may be a cancer subject that is more controversial than the screening and early detection of prostate cancer, but I don't know what that is,” said Peter H. Carroll, MD, MPH, Professor and Chair, Department of Urology, UCSF Helen Diller
Prostate Cancer Early Detection
Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
Prostate cancer is the most commonly diagnosed cancer in American men and the third leading cause of cancer-related deaths. However, the decision whether to pursue early detection of prostate cancer is complex; because not all men with prostate cancer will die of this disease, treatment is not necessary for some. These guidelines are intended to help men and clinicians choose a program for early detection of prostate cancer and make decisions about the need for prostate biopsy.
For the most recent version of the guidelines, please visit NCCN.org
Point/Counterpoint: Early Detection of Prostate Cancer: Do the Benefits Outweigh the Consequences?
Peter R. Carroll and Andrew J. Vickers
, and active surveillance for men with low-risk disease. Both Drs. Carroll and Vickers are members of the NCCN Guidelines Panel for Prostate Cancer Early Detection. Randomized Trials on PSA Screening The results of 2 key trials (from the United
